Insmed reported $361.01M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Cytokinetics USD 199.18M 3.27M Mar/2026
DBV Technologies USD 54.3M 2.5M Jun/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Insmed USD 361.01M 107.87M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026